Esophageal and Esophagogastric Junction Cancer

1.      Liam Zakko, Lori Lutzke, Kenneth K Wang, Screening and Preventive Strategies in Esophagogastric Cancer: Surg Oncol Clin N Am. 2017 Apr;26(2):163–178. 

2. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499-2509.

3. Weusten Bas LAM et al. Diagnosis and management Barrett esophagus: European . Society of Gastrointestinal Endoscopy (ESGE) Guideline Endoscopy 2023; 55: 1124–1146

4. Graham DY Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82:228-231.

5. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.

6. Mats Lindblad, Christine Jestin, Jan Johansson, David Edholm, Gustav Linder, Multidisciplinary team meetings improve survival in patients with esophageal cancer, Diseases of the Esophagus, 2024;,doae061.

7.      van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al. Staging investiga- tions for oesophageal cancer: ameta-analysis. Br J Cancer 2008; 98(3):547–557.

8. Flamen P, Lerut A, Van Cutsem E, De Wever W,  Bormans G, Hiele M, De Leyn P, Van Raemdonck  D,et al.Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000 Sep 15;18(18):3202-10. doi: 10.1200/JCO.2000.18.18.3202. PMID: 10986052.

9. Li X, Wang Y, Kong M, Lin J. Systematic review and meta-analysis of endoscopic ultrasonography in staging diagnosis of esophageal cancer after neoadjuvant radiotherapy and chemotherapy. J Gastrointest Oncol. 2022 Aug;13(4):1525-1540. doi: 10.21037/jgo-22-437. PMID: 36092358; PMCID:PMC9459206.

10. Riedel M, Stein HJ, and Mounyam L, et al (2000) Bronchoscopy in the preoperative staging of esophageal cancer below the tracheal bifurcation: a prospective study Eur Respir J 16(1) 134–139

11. Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus.2016;29(8):913-919.

12. Pan H, Cai S, Ji J, Jiang Z, Liang H, Lin F, et al. The impact of nutritional status, nutritional risk, and   nutritional treatment on clinical outcome of 2248 hospitalized cancer patients: a multi-center, prospective cohort study in Chinese teaching hospitals. Nutr Cancer 2013;65:62e70.

13. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes:    a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005;23: 1431e8.

14. Langius JA, Zandbergen MC, Eerenstein SE, van Tulder MW, Leemans CR, Kramer MH, et al. Effect of nutrition therapy on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo) radiotherapy: a systematic review. Clin Nutr 2013;32:671e8.

15. Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, et al. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol R Coll Radiol 2005;17: 639e45.

16.Marcy PY, Magne N, Bensadoun RJ, Bleuse A, Falewee MN, Viot M, et al. Systematic percutaneous fluoroscopic gastrostomy for concomitant radio chemotherapy of advanced head and neck cancer: optimization of therapy. Support Care Cancer 2000;8:410e3.

17.Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243e74

18.Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:842e57

19.Bozzetti F, Santarpia L, Pironi L, Thul P, Klek S, Gavazzi C, et al. The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multicenter observational study with prospective follow-up of 414 patients. Ann Oncol 2014;25:487e93.

20.Scolapio JS, Ukleja A, Burnes JU, Kelly DG. Outcome of patients with radiation enteritis treated with home parenteral nutrition. Am J Gastroenterol 2002;97:662e6.

21.Mortensen K, Nilsson M, Slim K, Schafer M, Mariette C, Braga M, et al., Enhanced Recovery After Surgery (ERAS®) Group. Consensus guidelines for enhanced recovery after gastrectomy: enhanced recovery after surgery (ERAS®) society recommendations. Br J Surg 2014;101:1209e29 

22. di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018;154(2):421-436.

23. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017;49(2):191-198.

24.. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(9):829-854.

25. Yamashina T, Ishihara R, Nagai K, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol. 2013;108(4):544-551.

26. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084.

27.Vincent J, Mariette C, Pezet D, et al. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: chemoradiation followed by surgery versus chemoradiation alone. Eur J Cancer. 2015;51(13):1683-1693.

28. Jiaxin Li, Yibin Jia, Yufeng Cheng, Jianbo Wang, Chemoradiotherapy vs radiotherapy for nonoperative early stage esophageal cancer: A seer data analysis,Cancer Med. 2020 May 22;9(14):5025–5034.

29. Xiaozheng Kang, Jianjun Qin, Ruixiang Zhang, et al, 2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer,AOE, Vol 4 (September 25, 2021)

30. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection comparedwith limited transhiatal resection for adenocarcinoma of the esophagus. N Engl JMed. 2002;347(21):1662-1669.

31. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593-1598.

32. van Hagen P, Hulshof MC, van Lanschot JJ, et al., CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer.N Engl J Med. 2012 May 31;366(22):2074-84

33. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167-1174.

34. Hulshof M, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECOStudy). J ClinOncol. 2021;39(25):2816-2824.

35. de Vos-Geelen J, Hoebers FJP, Geurts SME, et al. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol. 2020;59(8):895-903.

36.Csontos A, Fazekas A, Szakó L, Farkas N, Papp C, Ferenczi S, Bellyei S, Hegyi P, Papp A. Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis.World J Gastroenterol 2024; 30(11): 1621-1635.

 37.Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-195 

38.Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305-314.

39.Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J,Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. 

40. Paolet X, Oba K, Burzykowski T, et al; GASTRIC (Global Advanced/ Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-1737.

41.Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97.

42.Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, et al; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42.

43.Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced,unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011 Mar;14(1):50-5.

43.Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, et al; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86.

44.Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura ,et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. 

45.Sym SJ, Hong J, Park J, Cho EK, Lee JH, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol. 2013 Feb;71(2):481-8. 

46.Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001 Sep;31(9):419-23.

47.Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, et al; GO2 Trial Investigators. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1;7(6):869-877. 

48.Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011 Jun;67(6):1265-72.

49.Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2845-8.